Skip to content
INTENDED FOR RESEARCH PURPOSES ONLY

Melanotan 2 Injection Claims: Questions About Risk

Woman in a sun hat sitting on a beach near the water

Before accepting a claim about Melanotan 2 tanning injections, it helps to ask exactly what is being claimed. A product label, a personal experience and an official health statement answer different questions. This guide focuses on the risk and evidence questions that a promotional description cannot settle.

What does the source actually establish?

A testimonial may describe one person’s appearance or experience. It cannot establish general safety, a consistent result or a reduced risk of sunburn. A product listing can state what it says is in a package, but it is not independent testing of the contents. Follow a citation to its original source and check whether it concerns the same substance, format and outcome.

Cancer Research UK says Melanotan injections and nasal sprays are not safe to use and have not been tested for safety, quality or effectiveness. It also explains that a tan does not protect skin from UV radiation. A claim of “safer tanning” needs evidence for that specific outcome, not only an account of a darker appearance.

What does UK classification mean?

In its published response, the MHRA states that injectable and pen products containing Melanotan II are classified as medicines. It says unauthorised products lack safeguards for quality, safety and effectiveness, and discusses restrictions on their sale, supply and advertising. A seller’s description of handling or customer care is not the same as regulatory authorisation.

Claims about nasal products should be assessed separately because the MHRA describes a different classification condition for that format. The nasal and injection format comparison explains why a format distinction should not be read as a safety ranking.

Where can a reader go with a concern?

The science and risks guide collects the broader evidence. Someone concerned about a personal reaction should speak to an appropriately qualified health professional; the MHRA’s response explains its Yellow Card reporting route for suspected side effects.

Keep the source and the claim together: evidence about a substance, a product’s quality and an individual’s health concern should not be treated as interchangeable. An article on a sales site is not individual medical advice.